tiprankstipranks
Ionis Pharmaceuticals: FDA accepts NDA for eplontersen
The Fly

Ionis Pharmaceuticals: FDA accepts NDA for eplontersen

Ionis Pharmaceuticals announced that the U.S. FDA has accepted for review a New Drug Application for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy. The application has been given a Prescription Drug User Fee Act action date of Dec. 22, 2023.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on IONS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles